Kraig Biocraft Laboratories announced that it has deployed more than 700,000 BAM‑1 Alpha production hybrids, the genetically engineered silkworms that produce recombinant spider silk. The deployment follows an earlier announcement of a 1,000,000‑egg inventory and marks a substantial increase in production capacity, bringing the company closer to its goal of metric‑ton scale output.
The company’s CEO, Kim Thompson, said the milestone demonstrates disciplined, milestone‑driven execution: "This is exactly the kind of disciplined, structured, and milestone‑driven execution we set out to achieve. We laid out an ambitious plan to scale production to unprecedented levels, and we are now systematically delivering against that roadmap. The deployment of more than 700,000 BAM‑1 Alpha hybrids represents a major step forward as we move toward our goal of producing spider silk at metric ton levels."
Kraig’s production team reported that the BAM‑1 Alpha hybrids are performing exceptionally well, exceeding internal expectations for robustness and productivity. The hybrids’ high yield and reliability reduce unit costs as scale improves, positioning the company to secure its first revenue‑generating contracts and to compete in the $400 billion performance‑apparel and $200 billion technical‑textile markets.
The deployment is a key operational step that supports Kraig’s vertically integrated approach, which includes control over mulberry fields and multiple rearing centers. By scaling the number of hybrids in active production, the company can accelerate the transition from laboratory to commercial manufacturing, reducing time‑to‑market and improving cost efficiency.
This milestone signals progress toward Kraig’s broader goal of establishing a sustainable, high‑performance fiber platform that could disrupt large textile markets. The company’s focus on scalable production and cost control positions it to capture early commercial contracts and to build a competitive advantage in the emerging recombinant spider‑silk industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.